Immuron (IMRN) EBIAT (2016 - 2024)
Immuron's quarterly EBIAT came in at $1660259165.7 billion in Q4 2024, up 80082653894883.1% year-on-year from N/an in Q1 2024, and up 80082653894883.1% quarter-over-quarter from -$2.1 million in Q4 2023.
Immuron has reported EBIAT for 9 years, with the latest figure at $1660259165.7 billion in Q4 2024.
- For the quarter ending Q4 2024, EBIAT rose 80082653894883.1% year-over-year to $1660259165.7 billion; the trailing twelve-month figure through Dec 2024 stood at $1660259165.7 billion (up 24923787960206.56% YoY), and the FY2025 full-year result was -$3.4 million, up 25.69% from the prior year.
- EBIAT for Q4 2024 stood at $1660259165.7 billion, up from -$2.1 million in the prior quarter.
- The five-year high for EBIAT was $1660259165.7 billion in Q4 2024, with the low at -$6.5 million in Q2 2021.
- Average EBIAT over 5 years is $184473240.6 billion, with a median of -$1.9 million recorded in 2020.
- Year-over-year, EBIAT tumbled 15849.51% in 2023 and jumped 80082653894883.1% in 2024.
- Tracing IMRN's EBIAT over 5 years: stood at -$57387.7 in 2020, then soared by 77.0% to -$13196.5 in 2021, then rose by 1.5% to -$12998.4 in 2022, then plunged by 15849.51% to -$2.1 million in 2023, then jumped by 80082653894883.1% to $1660259165.7 billion in 2024.
- The last three EBIAT figures came in at $1660259165.7 billion (Q4 2024), -$2.1 million (Q4 2023), and -$2.5 million (Q2 2023), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -2.99 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | - |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 30.90 Mn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | -14.46 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 1.03 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | -3.63 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 727.20 Mn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 205.99 Mn |
| 10 | Immuron | 1.27 Bn | 1.27 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2024 | 1,660,259,165.67 Bn |
| Dec 31, 2023 | -2.07 Mn |
| Jun 30, 2023 | -2.53 Mn |
| Dec 31, 2022 | -12,998.41 |
| Jun 30, 2022 | -2.04 Mn |
| Dec 31, 2021 | -13,196.46 |
| Jun 30, 2021 | -6.46 Mn |
| Dec 31, 2020 | -57,387.72 |
| Jun 30, 2020 | -1.92 Mn |
| Dec 31, 2019 | -15,212.27 |
| Dec 31, 2018 | -1.58 Mn |
| Dec 31, 2017 | -1.47 Mn |
| Sep 28, 2017 | -4.76 Mn |
| Dec 31, 2016 | -2.57 Mn |
| Jun 30, 2016 | -3.28 Mn |